XGN Exagen

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen’s President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Company’s results at 4:30 PM ET (1:30 PM PT).

Interested parties may access the conference call by dialing (404) 267-0369 (U.S.) or (888) 437-3179 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at .

A replay of the conference call will be available until Thursday, August 18, 2022, at 11:59 PM ET (8:59 PM PT). Interested parties may access the replay of the conference call by dialing (201) 612-7415 (U.S.) or (877) 660-6853 (international) using passcode 13731768. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen (Nasdaq: XGN) is a leading provider of autoimmune diagnostic, prognostic, and monitoring testing solutions. Exagen is a patient focused, discovery driven organization built on the success of AVISE® testing and is investing in its product pipeline to support patients throughout their autoimmune diagnosis and treatment journeys. The goal at Exagen is to assist patients, physicians, and payors by enabling precision medicine. Exagen is located in San Diego County with clinical and research and development laboratories in Vista, CA.

For more information, please visit and follow on Twitter.

CONTACTS:

Investor Relations

Exagen Inc.

Ryan Douglas



760.560.1525

Company

Exagen Inc.

Kamal Adawi, Chief Financial Officer

760.477.5514



EN
21/07/2022

Underlying

XGNExagen

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exagen

 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Exagen Inc. to Participate in Fourth Quarter Investor Conferences CARLSBAD, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following upcoming investor conferences: 16th Annual Craig-Hallum Alpha Select Conference Date: November 18, 2025 Location: Sheraton New York Times Square Hotel Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Date: November 20, 2025 Location: Westin NY Grand Central - 212 E 42nd Street New York, NY 10017 About Exagen...

November 11, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. Reports Strong Q3 2025 Results

Exagen Inc. Reports Strong Q3 2025 Results CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates.   Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024(Unaudited, in thousands, except ASP data)  Revenue $17,244  $12,507  $49,944  $41,986 Gross margin  58.4%  55.8%  59.3%  58.7%Operating expenses $13,175  $11,644  $38,688  $34,888 Operating loss $(3,100) $(4,663) $(9,095) $(10,2...

November 4, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Announces Acceptance of Six Abstracts at 2025 American College ...

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds t...

October 23, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Announce Third Quarter 2025 Financial Results on Novemb...

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 CARLSBAD, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30, 2025, before the market opens on Tuesday, November 4, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Conference Call & Webcast: U.S. dial-in: 201-389-0918Intern...

October 21, 2025 1 EN
 PRESS RELEASE
Free
XGN EXAGEN

Exagen Inc. to Participate in Third Quarter Investor Conferences

Exagen Inc. to Participate in Third Quarter Investor Conferences CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following upcoming investor conferences: Canaccord Genuity 45th Annual Growth Conference Participation: Fireside Chat and 1X1 Meetings Date: Tuesday, August 12, 2025 Location: InterContinental Hotel in Boston, MA Cantor Global Healthcare Conference 2025 Participation: Fireside Chat and 1X1 Meetings Date: W...

August 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch